Rznomics Inc.
KOSDAQ-listed biotech company with a gene therapy platform based on trans-splicing ribozyme RNA technology.
As of 2026-10-11, Rznomics Inc. has 14 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2017 and listed on KOSDAQ in 2025, Rznomics is a gene therapy company. Its platform is based on trans-splicing ribozyme RNA technology, which cleaves target RNA and links it to a desired therapeutic gene RNA. The source document does not specify individual pipeline candidates, indications, or contract details.
Clinical trials
data.go.kr1 MFDS clinical trial authorisations · 2024 (Phase 1/2a 1)
- Phase 1/2aRZ-001 주, 발간시클로버 정2024-05-09
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 1/2 · Recruiting · 2024-12 · NCT06695026
Phase 1/2 · Recruiting · 2024-10 · NCT06102525
Phase 1/2 · Active not recruiting · 2022-07 · NCT05595473
Available · NCT06676891
R&D and key agreements
Source: DART corporate disclosureRNA 치환효소(Trans-splicing ribozyme) 플랫폼 · Mechanism cleaves target RNA and links a therapeutic gene RNA
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- Target site selection and P1 engineering enable highly efficient circular RNA production via end-to-end self-targeting and splicing.
Nucleic acids research · 2026-08 · Lee KH, Kim S, Cha J 외 1
- Delivery of Circular RNAs into Splenic Immune Cells via Intravenous Administration of Polyaspartamide Derivative Polyplexes.
ACS biomaterials science & engineering · 2026-04 · An JS, Lim SB, Lee KH 외 9
- Circular RNA as a New Vaccine Platform: Considerations, Challenges, and Perspectives.
Vaccines · 2026-02 · Lee KH, Lee J, Lee SW
- Development of RNA Aptamers That Inhibit the RNA-Dependent RNA Polymerase Activity of SARS-CoV-2 Strains In Vitro.
International journal of molecular sciences · 2025-11 · Song C, Lee SW
- In Vitro Self-Circularization Methods Based on Self-Splicing Ribozyme.
International journal of molecular sciences · 2024-08 · Lee KH, Lee NE, Lee SW
- Generation of hepatitis C virus-resistant liver cells by genome editing-mediated stable expression of RNA aptamer.
Molecular therapy. Methods & clinical development · 2023-12 · Kim TH, Lee SW
- Adenovirus VA RNAs impair maturation of primary microRNA.
The journal of gene medicine · 2023-12 · Kim JH, Lee CH, Lee SW
- Efficient circular RNA engineering by end-to-end self-targeting and splicing reaction using Tetrahymena group I intron ribozyme.
Molecular therapy. Nucleic acids · 2023-09 · Lee KH, Kim S, Song J 외 3
- Real-time monitoring strategies for optimization of in vitro transcription and quality control of RNA.
Frontiers in molecular biosciences · 2023-01 · Lee KH, Song J, Kim S 외 2
- Pros and Cons of In Vitro Methods for Circular RNA Preparation.
International journal of molecular sciences · 2022-10 · Lee KH, Kim S, Lee SW
Show 4 more publications
- Therapeutic Application of Genome Editing Technologies in Viral Diseases.
International journal of molecular sciences · 2022-05 · Kim TH, Lee SW
- Aptamers for Anti-Viral Therapeutics and Diagnostics.
International journal of molecular sciences · 2021-04 · Kim TH, Lee SW
- Targeted suicide gene therapy for liver cancer based on ribozyme-mediated RNA replacement through post-transcriptional regulation.
Molecular therapy. Nucleic acids · 2021-03 · Han SR, Lee CH, Im JY 외 10
- Group I Intron-Based Therapeutics Through Trans-Splicing Reaction.
Progress in molecular biology and translational science · 2018-01 · Lee CH, Han SR, Lee SW
Patents
KIPRIS · applicant-matchedPublished · 2026-03 · Application 1020260049319
Published · 2026-01 · Application 1020260013947
Published · 2026-01 · Application 1020260004260
PCT · Published · 2025-03 · Application PCT/KR2025/095047
Published · 2025-03 · Application 1020250035868
PCT · Published · 2025-01 · Application PCT/KR2025/000061
Published · 2025-01 · Application 1020250000360
US · Published · 2023-09 · Application 19108866
EP · Published · 2023-09 · Application 23863511.4
EP · Published · 2023-09 · Application 23863512.2
Show 32 more patents
PCT · Published · 2023-09 · Application PCT/KR2023/013376
PCT · Published · 2023-09 · Application PCT/KR2023/013375
Registered · 2023-09 · Application 1020230118503
Registered · 2023-09 · Application 1020230118437
US · Registered · 2022-10 · Application 18045860
US · Published · 2022-08 · Application 18681790
EP · Published · 2022-08 · Application 22853581.1
PCT · Published · 2022-08 · Application PCT/KR2022/011774
Withdrawn · 2022-08 · Application 1020220098089
Registered · 2022-03 · Application 1020220037572
EP · Published · 2022-03 · Application 22767538.6
PCT · Published · 2022-03 · Application PCT/KR2022/003377
Registered · 2022-03 · Application 1020220029918
US · Published · 2022-01 · Application 18034533
EP · Published · 2022-01 · Application 22742867.9
PCT · Published · 2022-01 · Application PCT/KR2022/001106
PCT · Published · 2022-01 · Application PCT/KR2022/001088
Registered · 2021-12 · Application 1020210193826
US · Registered · 2021-12 · Application 17646244
Withdrawn · 2021-08 · Application 1020210110740
EP · Published · 2021-07 · Application 21846099.6
PCT · Published · 2021-07 · Application PCT/KR2021/009555
Registered · 2021-07 · Application 1020210096986
Registered · 2021-03 · Application 1020210027335
EP · Published · 2021-02 · Application 21760156.6
US · Published · 2021-02 · Application 17626656
PCT · Published · 2021-02 · Application PCT/KR2021/002443
CN · Published · 2020-02 · Application 202010107272.7
US · Registered · 2020-02 · Application 16797663
EP · Published · 2020-02 · Application 20158701.1
Registered · 2020-02 · Application 1020200021014
EP · Registered · 2015-07 · Application 15847264.7
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot64
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 4 AI engines · last read Oct 10, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Rznomics Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition